These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 24944485)

  • 21. Second-line rescue treatment of
    Lin TF; Hsu PI
    World J Gastroenterol; 2018 Oct; 24(40):4548-4553. PubMed ID: 30386104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.
    Ciccaglione AF; Cellini L; Grossi L; Marzio L
    World J Gastroenterol; 2012 Aug; 18(32):4386-90. PubMed ID: 22969203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials.
    Zhang G; Zou J; Liu F; Bao Z; Dong F; Huang Y; Yin S
    Braz J Med Biol Res; 2013 Jul; 46(7):607-13. PubMed ID: 23903685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice.
    Shaikh T; Fallone CA
    Can J Gastroenterol Hepatol; 2016; 2016():7321574. PubMed ID: 27446864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
    Kim MS; Kim N; Kim SE; Jo HJ; Shin CM; Park YS; Lee DH
    BMC Gastroenterol; 2013 Sep; 13():138. PubMed ID: 24050512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
    Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG;
    Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
    Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate.
    Yoon H; Kim N; Lee BH; Hwang TJ; Lee DH; Park YS; Nam RH; Jung HC; Song IS
    Helicobacter; 2009 Oct; 14(5):77-85. PubMed ID: 19751431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment.
    Sacco F; Spezzaferro M; Amitrano M; Grossi L; Manzoli L; Marzio L
    Dig Liver Dis; 2010 Feb; 42(2):110-4. PubMed ID: 19846355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
    Zhou Y; Ye Z; Wang Y; Zhang Y; Tang Z; Yan W; Jiang Y; Huang Y
    Helicobacter; 2020 Apr; 25(2):e12679. PubMed ID: 31958193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
    Kim SB; Lee SH; Kim KO; Jang BI; Kim TN
    Korean J Gastroenterol; 2015 Nov; 66(5):261-7. PubMed ID: 26586348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study.
    Gu LY; Lin WW; Lu H; Chen XY; Ge ZZ; Li XB
    Helicobacter; 2011 Aug; 16(4):284-8. PubMed ID: 21762267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
    Yoon K; Kim N; Lee JW; Yoon H; Shin CM; Park YS; Lee DH
    Helicobacter; 2020 Jun; 25(3):e12685. PubMed ID: 32141173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study.
    Kwon YH; Kim N; Lee JY; Choi YJ; Yoon K; Nam RH; Suh JH; Lee JW; Lee DH
    Scand J Gastroenterol; 2016 Mar; 51(3):270-6. PubMed ID: 26452405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
    Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
    Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection.
    Miehlke S; Krasz S; Schneider-Brachert W; Kuhlisch E; Berning M; Madisch A; Laass MW; Neumeyer M; Jebens C; Zekorn C; Knoth H; Vieth M; Stolte M; Lehn N; Morgner A
    Helicobacter; 2011 Dec; 16(6):420-6. PubMed ID: 22059392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eradication Rate of
    Liu RP; Romero R; Sarosiek J; Dodoo C; Dwivedi AK; Zuckerman MJ
    South Med J; 2018 Jan; 111(1):51-55. PubMed ID: 29298370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication.
    Mansour-Ghanaei F; Joukar F; Naghipour MR; Forouhari A; Saadat SM
    World J Gastroenterol; 2015 Jan; 21(2):661-6. PubMed ID: 25593496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication.
    Ozturk O; Doganay L; Colak Y; Yilmaz Enc F; Ulasoglu C; Ozdil K; Tuncer I
    Arab J Gastroenterol; 2017 Jun; 18(2):62-67. PubMed ID: 28601610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
    Li Y; Huang X; Yao L; Shi R; Zhang G
    Wien Klin Wochenschr; 2010 Jul; 122(13-14):413-22. PubMed ID: 20628905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.